Press coverage about Inogen (NASDAQ:INGN) has been trending somewhat positive on Thursday, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inogen earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the medical technology company an impact score of 45.8150120024108 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Why Is Inogen (INGN) Down 7% Since its Last Earnings Report? (finance.yahoo.com)
- Inogen (INGN) Downgraded to Hold at Zacks Investment Research (americanbankingnews.com)
- Inogen (INGN) Earns Buy Rating from Needham & Company LLC (americanbankingnews.com)
- Global Medical Oxygen Concentrators Market 2018 – Invacare, Teijin Pharma, Chart Industries, Inogen, Yuyue Medical (newspharmaceuticals.com)
Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Piper Jaffray upgraded shares of Inogen from a “neutral” rating to an “overweight” rating in a report on Tuesday, February 20th. BidaskClub upgraded shares of Inogen from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $150.00 target price on shares of Inogen in a report on Tuesday. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $107.29.
Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. The company had revenue of $63.79 million during the quarter, compared to analysts’ expectations of $62.01 million. Inogen had a net margin of 8.42% and a return on equity of 13.47%. equities research analysts forecast that Inogen will post 1.6 EPS for the current fiscal year.
In other Inogen news, CFO Alison Bauerlein sold 11,718 shares of Inogen stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $115.87, for a total value of $1,357,764.66. Following the completion of the sale, the chief financial officer now owns 11,718 shares in the company, valued at approximately $1,357,764.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total transaction of $119,060.00. Following the completion of the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $119,060. The disclosure for this sale can be found here. Insiders sold a total of 159,369 shares of company stock valued at $19,038,125 in the last quarter. Corporate insiders own 5.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Inogen (INGN) Earns Daily Coverage Optimism Score of 0.11” was reported by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/2018/03/29/inogen-ingn-receives-news-impact-score-of-0-11/1970820.html.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.